Related Experiment Videos
The endothelin system and its potential as a therapeutic target in cardiovascular disease
Insights
Endothelin-1 (ET-1), a potent vasoconstrictor, plays a role in cardiovascular diseases. Therapies targeting ET-1, including receptor antagonists and enzyme inhibitors, are being developed for treatment.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Endothelin-1 (ET-1) is the most potent vasoconstrictor known.
- ET-1 also exhibits positive inotropic and chronotropic effects on the heart.
- It acts as a co-mitogen for cardiac and vascular myocytes.
Purpose of the Study:
- To review the components of the Endothelin system.
- To discuss the therapeutic potential of ET-1 antagonists and enzyme inhibitors.
- To evaluate the role of ET-1 in cardiovascular disease pathophysiology.
Main Methods:
- Cloning and characterization of ET-1 system components and receptors.
- Development of selective ET-converting enzyme inhibitors.
- Administration of ET receptor antagonists in early studies.
Main Results:
- The Endothelin system, including its isopeptides and receptors, has been extensively characterized.
- ET receptor antagonists show promise in addressing cardiovascular diseases.
- Selective ET-converting enzyme inhibitors are under development.
Conclusions:
- The Endothelin system is implicated in the pathophysiology of cardiovascular diseases.
- Both ET receptor antagonists and ET-converting enzyme inhibitors represent potential therapeutic strategies.
- Further research is needed to determine the optimal therapeutic approach for cardiovascular conditions involving ET-1.
Abstract:
Endothelin (ET)-1, an endothelium-derived peptide, is the most potent vasoconstrictor agent described to date. ET-1 also has positive inotropic and chronotropic effects in the heart and is a co-mitogen in both cardiac and vascular myocytes. The major elements of the system involved in formation of ET-1 and its isopeptides, as well as the receptors mediating their effects, have been cloned and characterised. Antagonists of the ET receptors are now available, and selective inhibitors of the ET-converting enzymes are being developed. Early studies using receptor antagonists support the involvement of ET-1 in the pathophysiology of several cardiovascular diseases. The relative merits of ET-converting enzyme inhibitors and receptor antagonists for the treatment of cardiovascular disease are discussed.